Concepedia

Author

J. Ives

Roche (United Kingdom)

Also Known As

J Ives, J. Ives, J.A.L. Ives, Juwan A. Ives, Juwan Ives

15

Publications

1.4K

Citations

9

H-Index

14

Concepts

All Affiliations

Roche (United Kingdom)University of MichiganGilead Sciences (United States)Hospital Infantil de México Federico GómezUniversity of Alberta
JI

About

J. Ives is an author at Roche (United Kingdom) specializing in medicine, virology, and pathogenesis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

722

2

Immunology

1

1

175

3

Microbiology

1

1

155

4

Molecular Biology

1

1

380

5

Nephrology

1

1

12

J. Ives

×

9

Publications

1.4K

Citations

9

H-Index

YearCitations

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients

Atul Humar, Y Lebranchu, Flavio Vincenti,

American Journal of Transplantation

2010

490

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo

J. Ives, Jackie Carr, Dirk B. Mendel,

Antiviral Research

2002

380

Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo

Jackie Carr, J. Ives, Lauren E. Kelly,

Antiviral Research

2002

175

Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets

M. Louise Herlocher, Jackie Carr, J. Ives,

Antiviral Research

2002

155

Valganciclovir Dosing According to Body Surface Area and Renal Function in Pediatric Solid Organ Transplant Recipients

W Vaudrya, R Ettengerb, P Jarac,

American Journal of Transplantation

2009

118

Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients

Mark D. Pescovitz, Robert B. Ettenger, C. Frederic Strife,

Transplant Infectious Disease

2009

58

Phenotypic Evaluation of Previously Uncharacterized Cytomegalovirus DNA Polymerase Sequence Variants Detected in a Valganciclovir Treatment Trial

Sunwen Chou, Guy Boivin, J. Ives,

The Journal of Infectious Diseases

2013

35

Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and/or film‐coated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease

Gustavo Varela‐Fascinetto, Corinne Benchimol, Rafael Reyes‐Acevedo,

Pediatric Transplantation

2016

21

The IMPACT Study: Valganciclovir Prophylaxis for until 200 Days Post-Transplant in High Risk Kidney Recipients Substantially Reduces the Incidence of CMV Disease.

Abhi Humar, Y Lebranchu, Flavio Vincenti,

Ghent University Academic Bibliography (Ghent University)

2009

12

Page 1